

Figure 1 A


N/C
VL/VH
anti-CD3
VH/VL
C/N
VL/VH
VH/VL
anti-target
VH/VL
VL/VH
C/N
VH/VL
VL/VH
anti-CD3
N/C

Figure 1 B


VH/VL
VL/VH
C/N
VH/VL
VL/VH
anti-CD3
C/N
VH/VL
VL/VH
anti-target
N/C
VH/VL
VL/VH
anti-target
N/C

Figure 1 C


anti-EpCAM x anti-CD3 polypeptide in monomeric form
anti-EpCAM x anti-CD3 polypeptide in dimeric form
% CD69-positive T cells
25
20
15
10
5
0
0 10-7 10-6 10-5 10-4 10-3 10-2 10-1 100 101 102 103
Concentration anti-EpCAM x anti-CD3 polypeptide (ng/ml)

Figure 2

Figure 3A


anti-CD19xanti-CD3 polypeptide in dimeric form
anti-CD19xanti-CD3 polypeptide in monomeric form
Cytotoxicity [%]
15
10
5
0
-5
-10
10^0
10^1
10^2
10^3
Concentration anti-CD19xanti-CD3 polypeptide [ng/ml]


anti-CD19 x anti-CD3 polypeptide in dimeric form
anti-CD19 x anti-CD3 polypeptide in monomeric form
Cytotoxicity [%]
30
20
10
0
10^{-1}
10^{0}
10^{1}
10^{2}
10^{3}
10^{4}
Concentration anti-CD19 x anti-CD3 polypeptide [ng/ml]

Figure 3B